Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma

BACKGROUND: For unresectable or metastatic melanoma, first-line ipilimumab has demonstrated long-term survival benefits over a 7-year period. First-line treatment with BRAF inhibitors has demonstrated efficacy in clinical trials with up to 3 years of follow-up. The long-term comparative efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun S., Rao, Sumati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827222/
https://www.ncbi.nlm.nih.gov/pubmed/27069772
http://dx.doi.org/10.1186/s40164-016-0039-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827222/
https://www.ncbi.nlm.nih.gov/pubmed/27069772
http://dx.doi.org/10.1186/s40164-016-0039-0

Ejemplares similares